Table 1 Comparison of tolterodine ER versus other antimuscarinics as reviewed in the 2012 AHRQ review [49]
From: Tolterodine extended release in the treatment of male oab/storage luts: a systematic review
Experimental drug versus standard drug | No. of studies | Patients | Relative risk (95% CI) |
|---|---|---|---|
Efficacy (cure of UI) | |||
Fesoterodine vs tolterodine ER | 2 | 3312 | 1.1 (1.04-1.16) |
Oxybutynin ER vs tolterodine ER | 3 | 947 | 1.11 (0.94-1.16) |
Solifenacin vs tolterodine ER | 1 | 1177 | 1.2 (1.08-1.34) |
Discontinuation due to adverse events | |||
Solifenacin vs tolterodine ER | 3 | 2755 | 1.28 (0.86-1.91) |
Fesoterodine vs tolterodine ER | 4 | 4440 | 1.54 (1.21-1.97) |